News

Real-World Data Shows Higher Feasibility Than In-Clinic Tests

Vous avez entre 18 et 65 ans. Vous êtes en bonne santé. Vous avez envie de faire progresser la recherche.

Vidéo de formation

Sysnav Healthcare supports the CTNNB1 Foundation for the Dragonfly Study, An Observational Study of CTNNB1 Syndrome Patient

At the 21st International Conference on Duchenne and Becker Muscular Dystrophy

Sysnav Healthcare is proud to announce that the Syde-derived digital endpoint SV95C has been acknowledged in the report “Unlocking the Value of Digital Measures in Drug Development” by HealthXL in partnership with Biofourmis.

EMA opinion marks the first qualification of a digital outcome measure for use as a primary endpoint in pivotal drug trials

The partnership aims to facilitate development of industry standard outcome measurements in diseases associated with movement impairments